FDA Panel Recommends Easing Access to Popular Peptide Drugs

A panel of federal health advisers on Thursday narrowly recommended easing access to several injectable peptides, including BPC-157, TB-500, and KPV, which are popular among wellness influencers and celebrities. This recommendation comes despite significant warnings from government scientists regarding the lack of demonstrated safety and efficacy for these substances. The panel voted 8-6, with one abstention, to suggest that the Food and Drug Administration (FDA) remove current restrictions that prevent pharmacies from producing these injectable peptides. If the FDA adopts this advice, it is anticipated that telehealth companies will increase their marketing of these chemicals for wellness and cosmetic applications. The composition of the panel itself has drawn attention, as more than six individuals with ties to the peptide industry, such as doctors, pharmacists, and consultants, were added prior to the meeting. David Pope, chief pharmacy officer of Xifin Pharmacy Solutions, stated after the vote on BPC-157, "I voted yes because it’s time to put this decision back in the hands of the patient, the physician and the pharmacist." The panel is scheduled to vote on three additional peptides on Friday. While the FDA is not obligated to follow the panel's advice, it typically does. FDA scientists have expressed strong reservations, citing a scarcity of data supporting the safe medical use of BPC-157, TB-500, and similar compounds. Panel members with academic backgrounds, as opposed to direct involvement in the peptide industry, largely voted against these substances.